Advertisement
UK markets closed

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     

  • AIM

    755.28
    +2.16 (+0.29%)
     

  • GBP/EUR

    1.1679
    +0.0022 (+0.19%)
     

  • GBP/USD

    1.2494
    -0.0017 (-0.13%)
     

  • Bitcoin GBP

    50,660.77
    -946.57 (-1.83%)
     

  • CMC Crypto 200

    1,304.48
    -92.06 (-6.59%)
     

  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     

  • DOW

    38,239.66
    +153.86 (+0.40%)
     

  • CRUDE OIL

    83.66
    +0.09 (+0.11%)
     

  • GOLD FUTURES

    2,349.60
    +7.10 (+0.30%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

GSK seeks U.S. approval for shingles vaccine Shingrix

Reuters - UK Focus

LONDON, Oct (HKSE: 3366-OL.HK - news) 24 (Reuters) - GlaxoSmithKline (Other OTC: GLAXF - news) said on Monday it had filed its shingles vaccine Shingrix for U.S. regulatory approval, bringing the potential blockbuster a step closer to market.

Shingrix is viewed by analysts as among the British drugmaker's most promising experimental products, since it has shown greater protection among older recipients than Merck (Jakarta: 28586808.JK - news) & Co's rival shot Zostavax.

GSK said it planned to file Shingrix for European and Canadian approval before the end of this year, with Japan following in 2017.

(Reporting by Ben Hirschler; Editing by Susan Fenton)